AUT 00063

Drug Profile

AUT 00063

Alternative Names: AUT-00063

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Autifony Therapeutics
  • Class Small molecules
  • Mechanism of Action Shaw potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hearing loss; Tinnitus

Highest Development Phases

  • Phase II Hearing loss; Tinnitus

Most Recent Events

  • 01 Apr 2017 Autifony Therapeutics completes a phase II trial in Hearing loss in United Kingdom (PO) (NCT02832128)
  • 01 Jun 2016 Autifony Therapeutics completes a phase II trial for Hearing loss (In adults, In the elderly) in USA (NCT02345031)
  • 10 Mar 2016 Phase-II clinical trials in Hearing loss in United Kingdom (PO) (EudraCT2015-003929-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top